How to Get Addyi (Flibanserin) in California

What Addyi Is and Why It Requires a Special Prescribing Process

Flibanserin (Addyi) is the only FDA-approved non-hormonal treatment for generalized acquired hypoactive sexual desire disorder in premenopausal women. The drug acts on serotonin 1A and 2A receptors and, to a lesser degree, on dopamine D4 receptors, lowering the activity of inhibitory pathways while raising excitatory tone in sexual-desire circuitry. It does not work like a hormonal agent, and it produces no acute effect on a per-encounter basis. You take it every night at bedtime, and the clinical benefit accumulates over four to eight weeks.

The FDA approved flibanserin in August 2015 under the brand name Addyi, manufactured by Sprout Pharmaceuticals. Approval came with a Risk Evaluation and Mitigation Strategy (REMS) because of the risk of severe hypotension and syncope when flibanserin is combined with alcohol or with moderate-to-strong CYP3A4 inhibitors. The REMS requirement means your prescriber, your pharmacy, and (if applicable) your mail-order distributor must all be enrolled in the Addyi REMS program before a prescription can be dispensed.

This is not an unusually burdensome process. It simply means you cannot call any random pharmacy and pick it up the same afternoon. Planning for a 3-to-7-business-day window from prescription to delivery is realistic for most California patients.

Clinical Evidence Supporting Flibanserin

Three key Phase 3 trials, BEGONIA, VIOLET, and DAISY, provided the efficacy data the FDA used to evaluate Addyi. The BEGONIA trial (N=1,378) randomized premenopausal women with HSDD to flibanserin 100 mg at bedtime versus placebo for 24 weeks. Women on flibanserin reported a statistically significant increase in satisfying sexual events (SSEs) versus placebo, with a mean difference of approximately 0.5 SSEs per month (P<0.001) and a meaningful reduction in distress scores on the Female Sexual Distress Scale-Revised. The effect size was modest in absolute terms, which is consistent with how HSDD treatment works: the goal is a clinically meaningful shift in desire and distress, not a dramatic single-encounter change.

The FDA's own summary of the BEGONIA, VIOLET, and DAISY trials concluded that responder rates on the Patient Global Impression of Improvement scale were 47 to 60 percent for flibanserin versus 27 to 41 percent for placebo across the three studies. That difference was statistically significant and formed a core part of the benefit-risk determination.

The American College of Obstetricians and Gynecologists (ACOG) notes in its guidance on female sexual dysfunction: "Flibanserin is an option for premenopausal women with generalized acquired HSDD who have not responded to other interventions, provided they understand the alcohol restriction." That guidance is available through the ACOG clinical resources portal.

Step-by-Step: How to Get an Addyi Prescription in California

Getting flibanserin in California follows a predictable four-stage sequence. Each stage has a defined task, and knowing what to expect at each one eliminates most of the confusion patients report.

Stage 1: Find a REMS-enrolled prescriber. Your prescriber must have completed the Addyi REMS certification before writing the prescription. Many California-licensed MDs, DOs, NPs, and PAs who work in women's health, gynecology, or sexual medicine have already done this. Telehealth platforms operating under California law can also provide this visit, provided the visit is synchronous (live video or phone) and the prescriber holds an active California license. The Medical Board of California and the California Board of Registered Nursing both permit telehealth prescribing for medications with REMS, as long as the REMS conditions themselves are satisfied.

Stage 2: Complete required screening. Before writing the prescription, your provider will confirm you are premenopausal, that your HSDD is generalized and acquired (not situational), and that the condition causes you meaningful personal distress. They will also screen for alcohol use disorder (a contraindication) and review your medication list for CYP3A4 inhibitors such as fluconazole, ketoconazole, or erythromycin. No blood labs are mandatory by the FDA REMS, but many California providers order a basic metabolic panel or liver function tests as clinical due diligence, particularly if you take other medications metabolized by CYP3A4.

Stage 3: Pharmacy dispensing through a REMS-certified outlet. Your prescriber sends the prescription to a REMS-certified pharmacy. Several large pharmacy chains in California, including specialty mail-order services, maintain this certification. The pharmacist is required to counsel you on the alcohol restriction before dispensing. For mail-order fulfillment, most patients in California receive the medication within 3 to 7 business days of the prescription being processed.

Stage 4: Insurance or self-pay. If you have commercial insurance, Addyi's manufacturer offers a co-pay savings card that may bring your monthly cost to as low as $25 for eligible patients. If you are enrolled in Medi-Cal, the drug is covered under the formulary but requires prior authorization (details in the next section). Cash-pay pricing at most California pharmacies runs between $400 and $500 per month for a 30-tablet supply. GoodRx coupons reduce that figure at participating REMS-certified pharmacies, though discount coupons cannot be combined with Medi-Cal.

Telehealth Access for Addyi in California

Telehealth prescribing of flibanserin is fully legal in California. The Telehealth Advancement Act of 2011 and its subsequent amendments allow California-licensed prescribers to evaluate and treat patients via live video, and nothing in the Addyi REMS prohibits telehealth initiation. The REMS simply requires that the prescriber complete the online certification and that the pharmacist counsel the patient before dispensing.

Several national telehealth platforms hold California medical group licenses and have at least one REMS-enrolled prescriber on their clinical staff. When evaluating platforms, confirm three things: the platform's prescribers are licensed in California (not just another state), the platform has a relationship with a REMS-certified pharmacy that ships to California ZIP codes, and the platform provides the required pharmacist counseling either through the dispensing pharmacy or through a licensed pharmacist on staff.

For patients in rural California counties where in-person gynecology access is limited, telehealth is often the fastest route. A synchronous video visit, a REMS-compliant prescription, and mail-order delivery from a certified pharmacy can complete the entire process without a single in-person step.

The California Department of Consumer Affairs has affirmed that nurse practitioners and physician assistants operating under their own authority (for NPs under AB 890) may prescribe Schedule IV and non-scheduled medications, including REMS medications, within their scope of practice. Flibanserin is not a controlled substance (it is not scheduled), so NPs and PAs face no additional scheduling barriers beyond the REMS itself.

Who Can Prescribe Addyi in California: MD, DO, NP, and PA Rules

Any California-licensed and REMS-enrolled healthcare provider with prescriptive authority may write for flibanserin. That includes:

• MDs and DOs (unrestricted prescriptive authority)
• Nurse practitioners holding an Advanced Practice Registered Nurse (APRN) license under California BRN (full practice authority under AB 890 after transition period, or collaborative practice)
• Physician assistants holding a PA license under the Physician Assistant Board (prescribing under a physician supervision agreement or, for qualifying PAs, under the updated PA Practice Act)

The REMS program itself does not distinguish by provider type. The enrollment form asks for the provider's DEA number (if applicable) and state license number, both of which NPs and PAs hold. There is no requirement that the prescribing provider be a physician specifically. This matters for California patients because NP-led telehealth practices are increasingly common and provide equal access for Addyi prescribing.

Prior Authorization for Medi-Cal Patients

Medi-Cal covers flibanserin for premenopaidal women with a documented HSDD diagnosis, but a prior authorization request is required before the pharmacy can fill the prescription. The PA process for Medi-Cal typically involves the following documentation:

1. A confirmed diagnosis of HSDD coded as F52.0 (hypoactive sexual desire dysfunction) in the patient record.
2. Documentation that the condition is acquired (not lifelong) and generalized (not limited to a specific partner or context).
3. Confirmation that the patient is premenopausal, based on menstrual history or laboratory evidence (FSH, estradiol).
4. A statement that non-pharmacologic interventions (such as psychotherapy or couples counseling) were either tried and failed, or are being pursued concurrently.
5. Confirmation that the patient has been counseled on the alcohol restriction and that no contraindicated CYP3A4 inhibitors are concurrently prescribed.

The Medi-Cal Drug Utilization Review program processes most non-urgent PA requests within 3 to 5 business days. Expedited review (within 72 hours) is available if the prescribing provider documents clinical urgency. If the PA is denied, the patient and provider have appeal rights under the Medi-Cal fair hearing process, and a peer-to-peer call between the prescriber and the Medi-Cal medical director can often resolve disagreements about medical necessity.

For commercially insured California patients, the PA criteria vary by plan. Most large California insurers (Anthem Blue Cross of California, Blue Shield of California, Kaiser Permanente) follow criteria similar to Medi-Cal: confirmed HSDD diagnosis, premenopausal status, documented distress, and prior trial of counseling. The Sprout Pharmaceuticals patient support line (1-844-ADDYI-4U) can provide reimbursement navigation support and connect patients with a specialty pharmacy that manages PA submissions on their behalf.

503A Compounding of Flibanserin in California

A 503A compounding pharmacy is a state-licensed facility that compounds medications for individual patients based on a valid prescription. Several California-licensed 503A pharmacies compound flibanserin in strengths or formulations that differ from the commercially available 100 mg tablet, sometimes at lower cost than brand-name Addyi.

California's 503A pharmacies operate under the oversight of the California State Board of Pharmacy. Compounded flibanserin does not carry the Addyi brand name, has not been independently evaluated by the FDA for bioequivalence to the brand product, and is not subject to the Addyi REMS. That last point means the dispensing pharmacist at a 503A pharmacy is not obligated to provide the REMS-specified patient counseling, though responsible pharmacies typically counsel patients on the alcohol interaction anyway.

Patients should understand that compounded flibanserin may vary from the brand in dissolution rate and bioavailability. The FDA's guidance on compounding notes that 503A pharmacies must comply with USP standards for compounding quality but are not required to demonstrate bioequivalence to the reference listed drug. If cost is the primary driver, it is reasonable to ask a 503A pharmacy for pricing, with the understanding that the formulation is not FDA-approved and has not been tested in the BEGONIA, VIOLET, or DAISY trials.

Lab Work and Safety Screening Before Starting Addyi

The FDA REMS for flibanserin does not require specific laboratory tests before prescribing. The label does warn that moderate or severe hepatic impairment is a contraindication, because flibanserin is extensively metabolized by CYP3A4 and CYP2C19 in the liver, and impaired metabolism significantly raises plasma concentrations. See the full prescribing information on the FDA website.

In clinical practice, most California providers who are thorough about this prescription order:

• A comprehensive metabolic panel (CMP) to assess liver enzymes (AST, ALT, bilirubin) and establish a baseline.
• A validated alcohol-use screening tool such as the AUDIT-C. A score suggesting alcohol use disorder is a contraindication to flibanserin.
• A medication reconciliation review specifically looking for CYP3A4 inhibitors. Common examples include fluconazole, clarithromycin, itraconazole, and several HIV antiretrovirals. Co-prescribing any of these with flibanserin dramatically increases the risk of hypotension and syncope.

Some providers also order an FSH and estradiol to confirm premenopausal status, particularly in patients aged 45 to 55 where perimenopause is possible. The key trials enrolled only premenopausal women, and the FDA label is explicit that Addyi is not indicated for postmenopausal women.

Blood pressure at rest is worth documenting because hypotension is one of the most common adverse events. In the safety database, the incidence of hypotension and syncope in patients who consumed alcohol alongside flibanserin was approximately 4 times the rate seen in sober patients, which is why the alcohol restriction is written into both the REMS and the label.

What to Expect After Starting Addyi

Flibanserin does not produce an immediate effect. Most patients notice changes in desire and a reduction in distress-related to low desire after 4 to 8 weeks of consistent nightly use. The 24-week data from BEGONIA showed that responder rates continued to climb through week 8 before plateauing. If a patient sees no subjective benefit by week 8 of consistent use, re-evaluating the diagnosis and ruling out contributing factors (thyroid dysfunction, depression, relationship stressors, or inadequate sleep) is appropriate.

The most frequently reported adverse events in the trials were dizziness (11.4% flibanserin versus 2.9% placebo), somnolence (11.2% versus 2.9%), nausea (10.4% versus 3.9%), and fatigue (9.2% versus 5.5%). These figures come from the FDA-approved prescribing label. Taking the medication at bedtime, as directed, reduces the clinical impact of somnolence and dizziness because most of the peak plasma concentration is reached while the patient sleeps.

Patients should follow up with their prescribing provider at 4 weeks and again at 8 weeks to assess response, review alcohol adherence, and confirm no new medications have been added that interact with CYP3A4. If benefit is confirmed at 8 weeks, most providers continue the prescription with quarterly check-ins.

Transferring an Addyi Prescription to California

If you obtained an Addyi prescription in another state and have moved to California, or if you want to transfer an active prescription to a California-licensed pharmacy, the process is straightforward. Flibanserin is not a controlled substance, so no special interstate transfer rules apply beyond the standard pharmacy transfer process and the REMS certification requirement at the receiving pharmacy.

Call the California pharmacy you want to use, confirm they are REMS-certified for Addyi, and ask them to contact your previous pharmacy for the transfer. The receiving pharmacist will verify the original prescription, confirm the prescriber is still licensed and REMS-enrolled, and counsel you on the alcohol restriction before dispensing. Your original prescriber does not need to write a new prescription unless your previous state's prescription has expired or the remaining refills are exhausted.

If your original prescriber is not licensed in California, you will need a new prescription from a California-licensed provider. A single telehealth visit with a California REMS-enrolled provider is sufficient to generate a new prescription, and most telehealth platforms can schedule that visit within 24 to 48 hours.